X0607 3 2026-04-15 0 0001819133 Tango Therapeutics, Inc. TNGX 0002130408 Newcomb Jessica false C/O TANGO THERAPEUTICS, INC. 201 BROOKLINE AVE., SUITE 901 BOSTON MA 02215 false true false false Principal Accounting Officer Common Stock 67321 D Stock Option (Right to Buy) 4.26 2032-09-01 Common Stock 130000 D Stock Option (Right to Buy) 5.20 2033-03-01 Common Stock 31418 D Stock Option (Right to Buy) 2.67 2033-06-01 Common Stock 2000 D Stock Option (Right to Buy) 12.28 2034-02-01 Common Stock 74295 D Stock Option (Right to Buy) 3.13 2035-01-02 Common Stock 10000 D Stock Option (Right to Buy) 2.91 2035-02-03 Common Stock 126188 D Stock Option (Right to Buy) 8.93 2036-01-02 Common Stock 1000 D Stock Option (Right to Buy) 11.94 2036-02-02 Common Stock 153094 D The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. This option vests and becomes exercisable over a four-year period, at a rate of 25% on August 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option is fully vested and exercisable. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2025, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a four-year period, with the option shares vesting in 48 equal monthly installments beginning on January 14, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a one-year period, with the option shares vesting in 12 equal monthly installments beginning on November 23, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2027, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Exhibit 24: Power of Attorney /s/ Julie Fogarty, as attorney-in-fact 2026-04-24